AN2 Therapeutics plans Phase 2 epetraborole trial for polycythemia vera

ANTX•2026-10-21

AN2 Therapeutics plans to present the design of a Phase 2 trial evaluating oral epetraborole in patients with phlebotomy-dependent polycythemia vera on October 29, 2026.

AN2 Therapeutics plans Phase 2 epetraborole trial for polycythemia vera

1. Planned trial design

Related News

Community Trust Bancorp Q3 2026 net income falls 13% from prior quarter to $25.89 million

Steyr Motors says key terms of announced voluntary public tender offer remain unchanged

Abundia Global Impact Group outlines plan for commercial fuels project revenue by 2029

Neocloud shares gain as SpaceX, Super Micro results show strong AI demand

Red Violet publishes update to financial calendar